Enhancing autologous cellular therapy with ibrutinib in CLL patients
Iris de Weerdt
Ibrutinib combined with TGR-1202 in CLL and mantle cell lymphoma (MCL): preliminary results
Bendamustine plus rituximab vs. standard therapy for advanced CLL
PHILEMON: a step closer to using MRD to guide treatment decisions in mantle cell lymphoma (MCL)?
Understanding the drivers behind disease with the 100,000 Genomes Project